H.C. Wainwright analyst Joseph Pantginis downgraded Atreca to Neutral from Buy without a price target. The company announced a “drastic” corporate reorganization, revealing plans to restructure its operations with the aim of reducing costs and extending its operational timeline, the analyst tells investors in a research note. The firm’s prior valuation of Atreca was based solely on ATRC-101, which is now currently suspended or potentially discontinued outright in the future.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BCEL: